Summary
Selected cardiovascular and endocrine effects of the new oral vasodilator Ro 12-4713 have been evaluated in an acute single dose study. In five patients with essential hypertension, Ro 12-4713 caused a dose-dependent decrease in supine and upright blood pressure and an increase in heart rate. Initial effects occurred one to 2 h after drug ingestion and maximal effects were noted after five hours and persisted for at least 8 h. Blood pressure was normalized, and the antihypertensive and chronotropic effects persisted for 24 h after a dose of about 300 mg/1.73 m2. Plasma and urinary norepinephrine and plasma renin levels tended to be raised, whereas plasma and urinary epinephrine and plasma aldosterone did not change. Changes in supine heart rate were inversely correlated with changes in mean blood pressure (r=−0.60; P<0.02), and positively with those in plasma norepinephrine (r=0.55; P<0.05) and renin (r=0.62, P<0.01); changes in supine plasma renin level were also inversely correlated with those in mean blood pressure (r=−0.65; P<0.01), and positively with those in plasma norepinephrine (r=0.58; P<0.05). 24 h-urinary sodium excretion was significantly (P<0.001) decreased; it was positively correlated with mean blood pressure (r=0.51; P<0.05) and inversely with supine plasma renin activity (r=−0.63; P<0.01). In six normal subjects and six patients with essential hypertension, effective renal plasma flow and the renal clearance of sodium, potassium, calcium and uric acid were not significantly altered five hours after a dose of Ro 12-4713 of about 250 mg/1.73 m2; glomerular filtration rate tended to be slightly decreased, and filtration fraction was significantly (P<0.05) reduced in the hypertensive patients. At the same time blood pressure was decreased and plasma norepinephrine (P<0.01) and renin (ns) were slightly increased in both groups. Ro 12-4713 in a single oral dose of about 300 mg appeared to be a potent, long acting, hypotensive vasodilator.
Similar content being viewed by others
References
Gilmore E, Weil J, Chidsey C (1970) Treatment of essential hypertension with a new vasodilator in combination with betaadrenergic blockade. N Engl J Med 282: 521–527
Gerold M, Eigenmann R, Hefti F, Häusler G (1980) Ro 12-4713 — A new vasoactive antihypertensive with an unusual pattern of cardiovascular effects. World Conference on Clinical Pharmacology and Therapeutics, London
Gerold M, Eigenmann R, Hefti F, Daum A, Häusler G (1981) Cardiovascular effects of a novel vaso-active antihypertensive agent, Ro 12-4713. J Pharmacol Exp Ther 216: 624–633
Sealy JE, Gerten-Banes J, Laragh JH (1972) The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int 1: 240–253
Vetter W, Vetter H, Siegenthaler W (1973) Radioimmunoassay for aldosterone without chromatography: II. Determination of plasma aldosterone. Acta Endocrinol (Copenh) 74: 558–567
Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19: 1161–1174
Bertler A, Carlsson A, Rosengren E (1958) A method for the fluorometric determination of adrenaline and noradrenaline in tissue. Acta Physiol Scand 44: 273–292
Weidmann P, Beretta-Piccoli C, Ziegler WH, Keusch G, Glück Z, Reubi FC (1978) Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: Studies in normal subjects and patients with essential hypertension. Kidney Int 14: 619–628
Vorburger C, Riedwyl H, Reubi FC (1969) Vergleichende Studien zwischen den renalen Clearances von 51Cr-EDTA, Inulin und Natriumthiosulfat beim Menschen. Klin Wochenschr 47: 415–420
O'Malley K, Velasco M, Wells J, McNay JL (1975) Control Plasma renin activity and changes in sympathetic tone as determinants of minoxidil-induced increase in plasma renin activity. J Clin Invest 55: 230–235
Kaneko Y, Ikeda T, Takeda T, Ueda H (1967) Renin release during acute reduction of arterial pressure in normotensive subjects and patients with renovascular hypertension. J Clin Invest 46: 705–716
Davis JO (1973) The control of renin release. Am J Med 55: 333–350
Edide I, Løyning E, Kiil F (1973) Evidence for hemodynamic autoregulation of renin release. Circ Res 32: 237–245
Werning C, Vetter W, Weidmann P, Schweikert HU, Stiel D (1971) Effects of prostaglandin E1 on renin in the dog. Am J Physiol 220: 852–856
Grim CE, Luft FC, Grim CM, Klotman PE, Van Huysse J, Weinberger MH (1979) Rapid blood pressure control with minoxidil. Acute and chronic effects on blood pressure, sodium excretion, and renin-aldosterone system. Arch Intern Med 139: 529–533
Pratt JH, Grim CE, Parkinson CA (1979) Minoxidil increases aldosterone metabolic clearance in hypertensive patients. J Clin Endocrinol Metab 19: 834–837
Reubi FC (1978) Role of physical factors in the acute changes in renal function elicited by antihypertensive drugs. Eur J Clin Pharmacol 13: 185–193
Reubi FC (1977) Le retentissement rénal des traitements anti-hypertenseurs. Urol Nefrol 83: 296–302
Reubi FC (1950) Renal hypermia induced in man by a new phtalazine derivative. Proc Soc Exp Biol Med 73: 296–302
Onesti G, Brest AN, Novack P, Kasperian H, Moyer JH (1964) Pharmacodynamic effects of alpha-methyl-dopa in hypertensive subjects. Am Heart J 67: 32–38
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grimm, M., Weidmann, P., Meier, A. et al. Acute effects of a new vasodilator, Ro 12-4713, on blood pressure, plasma renin activity, aldosterone and catecholamine levels, and renal function in hypertensive and normal subjects. Eur J Clin Pharmacol 20, 169–177 (1981). https://doi.org/10.1007/BF00544594
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544594